

Can BCAT1 expression level help predict disease progression in chronic lymphocytic leukaemia

Steven J Coles, Alex J Wadley

Institute of Science & the Environment, University of Worcester, UK

Correspondence: Steven J Coles, Institute of Science and the Environment, University of Worcester, St Johns Campus, Henwick Grove, Worcester, UK, WR2 6AJ, Tel 01905 542577, Email economou.p@unic.ac.cy

Received: October 29, 2017 | **Published:** February 17, 2018

Copyright© 2018 Coles et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: CLL, lymphocyte, prognosis, oncogenesis, metabolism

Letter to the Editor

Chronic lymphocytic leukaemia (CLL) is the most common blood cancer in the UK, with an incidence of >3500 newly diagnosed cases per year resulting in >1000 deaths. Disease prevalence increases with age, where the majority of patients are >65 years old.¹ CLL is a largely indolent disease and is routinely staged according to the Binet system as follows; stage A (involving 0-2 lymphoid sites), stage B (involving 2-5 lymphoid sites) and stage C (platelets < 1x10¹¹/L or haemoglobin <10g/dL), the latter stage reflecting loss of bone marrow function.² Whilst for some stage A patients, the disease may remain stable for many decades (median life expectancy of 13 years), for others the disease progresses more rapidly.³ This observation likely reflects the genetic and molecular heterogeneity of CLL. As such there are several prognostic risk factors used to stratify newly diagnosed patients, which include; trisomy-12, 13q/17p/11q23 deletion, advanced stage, males>females, unmutated VH Ig genes, raised lactate dehydrogenase activity and expression of Zap70 and CD38.⁴ CLL is traditionally treated with a combination of chemotherapeutic reagents, namely, Fludarabine/Cyclophosphamide/Rituximab (FCR), however treatment remains challenging within the elderly population.¹ Lately the Brutan's tyrosine kinase inhibitor, Ibrutinib, has shown great promise for the treatment of CLL.⁵ However, exceptions are identified as well as treatment resistance prompting further research into CLL treatment strategies.⁶

Recently upregulation of the cytosolic isoform of branched-chain amino transferase (BCAT1) has been implicated in the disease progression of chronic myeloid leukaemia (CML).⁷ Hattori demonstrated that BCAT1 expression was required for maintenance of CML cells in an undifferentiated state, an important hallmark of cancer.⁸ This was achieved through metabolic reprogramming resulting in alterations in cellular α -ketoglutarate. Moreover, the authors showed that treating myeloid leukaemia cells with Gabapentin (BCAT1 inhibitor)⁹ reduced cell proliferation in colony assays. Taken together, these findings suggest that BCAT1 has an important role in CML leukaemogenesis, which offers therapeutic potential for BCAT1 inhibitors, such as gabapentin to form part of new treatment strategies

in CML. However, the implications of BCAT1 expression in CLL are currently unknown. Hence we investigated whether BCAT1 was over-expressed in CLL, and if so, was there any evidence to suggest that BCAT1 may be implicated in CLL disease progression.

To this end we analysed CLL patient microarray data available from the NCBI GEO (<https://www.ncbi.nlm.nih.gov/geo/>) for the expression of BCAT1 in peripheral blood or bone marrow mononuclear cells at point of diagnosis. The data set analysed herein was GEO accession GSE22762 (GPL570 platform), which consisted of 107 newly diagnosed censored CLL patients. The patient characteristics for this data set as stated in the original study published in¹⁰ had a median age of 63 (33-85) years, of which 66.4% were male, 51.5% were stage A, 24.8% were stage B and 23.8% were stage C according to the Binet classification system. Initially we stratified the CLL patients according to time to first treatment as follows; <100 days (poor), 100–1,000 days (medium) and >1,000 days (good), and searched for the top 250 most dysregulated genes using the GEO2R online analytical tool. Of the 44,754 probes sets available on the GPL570 platform, probe set 226517_{at} which corresponds to BCAT1 features in the top 100 most dysregulated genes (P=0.0002) according to our risk stratification. A complete list of the top 100 genes generated by this analysis is summarised in [Supplemental \(Table S1\)](#). We next evaluated whether there was any significant difference in BCAT1 relative expression between our 3 risk groups. The data presented in Figure 1 illustrates a significantly higher relative BCAT1 expression in patients where time to first treatment was <100 days compared with patients where time to first treatment was >1,000 days (P<0.001). To corroborate this finding, the data was imported into Gene Spring (Agilent Technologies) for normalisation and background correction using the GC-RMA algorithm. The Gene Spring normalised analysis agreed with the relative expression analysis and displayed significantly higher BCAT1 expressing in the <100 days group compared with the >1,000 days group (P<0.001). Since expression of CD38 and Zap70 have major impact on disease progression in CLL, we wanted to verify whether there was an association between CD38/Zap70 expression and BCAT1 using linear regression analysis. The data show no correlation between Zap70 expression and BCAT1 (R²=0.028, P=0.087). However, a very weak positive correlation was detected for CD38 and BCAT1 expression (R²=0.167, P<0.001). This suggests that BCAT1 expression is independent to Zap70 and CD38.




Figure 1 BCAT1 expression levels stratified according to time to first treatment. Microarray data from GEO accession GSE22762; GPL570 platform was stratified according to time to first treatment; <100 days (n=18), 100-1000 days (n=37) and >1000 days (n=40) and analysed for BCAT1 expression (226517_at probe set). The top 100 most dysregulated genes according to this stratification are summarised in Supplemental Table S1. a) Relative BCAT1 expression level at each time point analysed using NCBI GEO2R online tool. b) Normalised BCAT1 expression analysed in GeneSpring (Agilent Technologies) with CG-RMA background correction. c) Linear regression analysis comparing BCAT1 relative expression with CD38 relative expression (205692_s_at probe set). d) Linear regression analysis comparing BCAT1 relative expression with ZAP70 relative expression (214032_at probe set). n=95 for each plot. *P<0.05, ***P<0.001, data analysed by one way-ANOVA with Tukey's Multiple Comparison Test.


In adults BCAT1 expression is restricted to the central nervous system, where it has a pivotal role in glutamate metabolism, however the structural homologue, mitochondrial branched-chain amino transferase (BCAT2) is ubiquitously expressed.¹¹ This suggests a developmental role for BCAT1, and 'housekeeping' role for BCAT2. Thus to further investigate BCAT1 expression in CLL, we compared expression levels between haematopoietic stem cells (HSC), CLL patient cells and healthy donor bone marrow (BM) for both BCAT1 and BCAT2 expression. Microarray data sets analysed were obtained from the NCBI GEO and included GEO accession GSE13496 (GPL96 platform) for HSC analysis and GSE4619 (GPL570 platform) for healthy BM analysis. Data sets were imported into Gene Spring for normalisation and CG-RMA correction prior to BCAT1/BCAT2 gene expression analysis. The data presented in (Figure 2) shows that both HSC and CLL cells express significantly more BCAT1 compared with BM from healthy age matched donors (P<0.01). This finding suggests that BCAT1 expression is lost during normal bone marrow differentiation, and supports the notion presented for CML that BCAT1 expression maintains the leukemic cell a less differentiated state.⁷ These data are in contrast to BCAT2, where no significant difference in expression was detected between CLL and healthy BM (P>0.05). Furthermore, no correlation between BCAT1 and BCAT2

expression was detected in CLL ($R^2=-0.016$; $P=0.202$), suggesting that expression levels are independent. A summary of BCAT1 and BCAT2 normalised expression in CLL linked to our original risk stratification is presented in (Table 1). The data presented is the averaged normalised expression for each BCAT probe set and shows that BCAT1 expression (not BCAT2) is linked to disease progression, i.e. patients with time to first treatment <100 days have significantly higher BCAT1 expression levels.

Finally, Kaplan-Meier analysis was performed to evaluate whether BCAT1 expression level could predict CLL patient overall survival (OS) and time to first treatment (Figure 3). For this analysis, CLL patients were stratified according to normalised BCAT1 expression level; BCAT1(hi) 2.178 to 4.209 (top quartile) and BCAT1(lo) -1.187 to -2.686 (bottom quartile). There were a total of 27 CLL patients in each arm. The data presented in Figure 3 show that BCAT1(hi) CLL patients have a significantly worse OS compared with BCAT1(lo) ($P=0.0015$; Hazard Ratio=9.381) and a significantly shorter time to first treatment ($P=0.0147$; Hazard Ratio=3.283). This is in contrast to BCAT2, where no impact was observed when comparing BACT2(hi) with BCAT2(lo) expressers ($P>0.05$). It must be noted that the data presented here needs further risk stratification evaluation and assessment of BCAT1 protein expression at the cellular level.

Table I Risk stratification characteristics for BACT expression

Patient Group (prognosis)	Days to First treatment	Gene	Probe Sets	Mean Normalised Expression (log ₂)*
Good (n=40)	>1000	BCAT1	226517_at; 225285_at; 214452_at; 214390_s_at	-0.427±1.77
		BCAT2	215654_at; 203576_at	0.058±0.306
Medium (n=37)	100 to 1000	BCAT1	226517_at; 225285_at; 214452_at; 214390_s_at	0.582±1.75
		BCAT2	215654_at; 203576_at	0.050±0.382
Poor (n=18)	<100	BCAT1	226517_at; 225285_at; 214452_at; 214390_s_at	1.67±1.86
		BCAT2	215654_at; 203576_at	-0.056±0.262

**Figure 2** Comparison of normalised BCAT1 and BCAT2 expression level between CLL cells, haematopoietic stem cells (HSC) and healthy donor bone marrow (BM).

- BCAT1 normalised expression level for 107 CLL patients (GEO accession GSE22762; GPL570 platform) was compared with 12 normal HSC samples (GSE13496; GPL96 platform) and 10 healthy BM samples (GSE4619; GPL570 platform).
- Respective data comparing normalised BCAT2 expression level.
- Linear regression analysis between normalised BCAT1 expression and normalised BCAT2 expression in CLL ($R^2=-0.016$; $P=0.202$). ** $P<0.01$, *** $P<0.001$, data analysed by one way-ANOVA with Tukey's Multiple Comparison Test.




Figure 3 Kaplan-Meier analysis evaluating BCAT1 and BCAT2 expression in CLL. Patients were stratified according to BCAT1 (hi); 2.178 to 4.209 (top quartile) and BCAT1 (lo); -1.187 to -2.686 (bottom quartile), based on averaged \log_2 normalised expression values for each BCAT1 probe set (226517_at; 225285_at; 214452_at and 214390_s_at).

- Charts show the impact of BCAT1 expression on overall survival and
- Time to first treatment.
- For comparison, the impact of BCAT2 was evaluated. Patients were stratified according to BCAT2 (hi); 0.266 to 0.973 (top quartile) and BCAT2 (lo); -0.183 to -0.802 (bottom quartile), based on averaged \log_2 normalised expression values for each BCAT2 probe set (215654_at; 203576_at). Charts show the impact on overall survival and
- Time to first treatment. Patients that express intermediate levels of BCAT have been included for comparison: BCAT1 (int); -1.132 to 1.790 (interquartile range) and BCAT2 (int); -0.182 to 0.255 (interquartile range) respectively.

Taken together, the data presented here using GEO microarray data sets demonstrates that BCAT1 is significantly dysregulated in CLL. Patients <100 days before first treatment expressed significantly higher levels of BCAT1 compared with patients >1,000 days before first treatment. We also showed that BCAT1 expression is lost through normal blood cell differentiation, suggesting that BCAT1 may have a functional role in normal haematopoiesis. Finally, disease progression may be predicted when CLL patients are stratified according to BCAT1 expression level. These findings align with recent studies evaluating the role of BCAT1 in CML and other cancers such as; glioma,¹² breast cancer,¹³ hepatocellular carcinoma¹⁴ and prostate cancer.¹⁵ The clinically approved drug Gabapentin, which can inhibit BCAT1 activity, may therefore have a future role in the treatment of these cancers. Furthermore, stratification of patients according to BCAT1 expression level may be important clinically and help predict disease progression in CLL.

Conflict of interest

The authors declare no conflict of interest.

Author contribution

SC performed all data analysis. SC and AW contributed to the preparation of the final manuscript.

References

- Oscier D, Dearden C, Erem E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. *Br J Haematol.* 2012;159(5):541–564.
- Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. *Am J Hematol.* 2017;92(9):946–965.
- Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. *Br J Haematol.* 2012;156(4):499–507.
- Mainou-Fowler T, Dignum HM, Proctor SJ, et al. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). *Leuk Lymphoma.* 2004;45(3):455–462.
- Brown JR. Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials. *Curr Hematol Malig Rep.* 2013;8(1):1–6.

6. Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. *Ann Hematol.* 2017;96(7):1175–1184.
7. Hattori A, Tsunoda M, Konuma T, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. *Nature.* 2017;545(7655):500–504.
8. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell.* 2011;144(5):646–674.
9. Goto M, Miyahara I, Hirotsu K, et al. Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. *J Biol Chem.* 2005;280(44):37246–37256.
10. Herold T, Jurinovic V, Metzeler KH, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. *Leukemia.* 2011;25(10):1639–1645.
11. Sweatt AJ, Garcia-Espinosa MA, Wallin R, et al. Branched-chain amino acids and neurotransmitter metabolism: Expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus. *J Comp Neurol.* 2004;477(4):360–370.
12. Tönjes M, Barbus S, Park YJ, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nat Med.* 2013;19(7):901–908.
13. Thewes V, Simon R, Hlevnjak M, et al. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER α -negative breast cancer. *Oncogene.* 2017;36(29):4124–4134.
14. Xu M, Liu Q, Jia Y, et al. BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. *Oncol Lett.* 2016;12(4):2648–2656.
15. Zhu W, Shao Y, Peng Y. MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer. *Mol Carcinog.* 2017;56(6):1570–1577.